Toggle navigation
Content library
Alzheimer's & Neurodegenerative Diseases
Clinical Assessment
Fluid Biomarkers
Imaging
Management of ARIA
Biostatistics
Case Studies
Treatment
Congresses
BiogenAD symposium
AD Symposium Comprehensive Cognitive Assessment 2020 CA
AD Symposium Evaluating Pathological Biomarkers 2020 CA
AD Symposium Healthcare System Readiness 2020 CA
AD Symposium Case Study2020 CA
Preparing the health system: where do we go from here?
Leveraging biomarkers for an earlier diagnosis of AD
The challenges we face in advancing the AD clinical and research landscape
Pursuing a memory complain: how do we better detect and refer patients earlier?
Learning Programs
Other Resources
Cookies
Subscribe
Thank you
Expert Perspectives
To what extent do you believe the guidelines presented (WHO and Lancet Commission) will have an impact on clinical practice in Alzheimer’s disease?
What is the most important scientific update in terms of advancing the AD field from AAIC, and why?
What is your key takeaway for the Alzheimer’s disease community from AAIC?
What updates from AAIC do you consider to have the greatest impact on your clinical practice, and why?
What updates from CTAD do you consider to have the greatest impact on your clinical practice, and why? Perspectives from Dr. Sophie Auriacombe
What updates from CTAD do you consider to have the greatest impact on your clinical practice, and why? Perspectives from Dr. John Morgan
What is your key takeaway for the Alzheimer's disease community from CTAD? Perspectives from Jill Rasmussen
What is your key takeaway for the Alzheimer's disease community from CTAD? Perspectives from Dr. Collin Liu
Register for our events
Name
*
Email
*
Specialty
*
Select...
Neurologist
Geriatrician
Geriatric psychiatrist
Nurse
Pharmacist
Other
Other specialty
Province
Please specify
Alberta
British Columbia
Manitoba
New Brunswick
Newfoundland
Nova Scotia
Ontario
Prince Edward Island
Quebec
Saskatchewan
Northwest Territories
Nunavut
Yukon
Please select all the events you would like to attend. *
Navigating an early diagnosis of Alzheimer’s disease: identifying underlying pathologies
Dr. Jennifer Ingram & Dr. Andrew Kirk
Wednesday, May 18, 2022 – 7 pm to 8:30 pm ET
This webinar will present an overview of Alzheimer’s disease (AD). It provides key facts and figures about dementia and AD in Canada including the socioeconomic burden associated with dementia due to AD and the populations and individuals at high risk of dementia and/or facing barriers to equitable care. The presentation then goes on to describe the various mechanisms that contribute to neurodegeneration and AD, the various types of AD, as well as the risk factors for AD, both non-modifiable and potentially modifiable, and the possible protective factors. The diagnostic pathway and stages of AD are also examined, followed by an exploration of the current treatment options and diagnostic guidelines.
Investigating a cognitive complaint: measures leading to a timely referral in early Alzheimer’s disease
Dr. Michael Borrie & Dr. Jennifer Ingram
Wednesday, June 1, 2022 - 7 pm to 8:30 pm ET
This webinar will describe the various steps involved in the clinical assessment of a patient with a cognitive complaint or informant concern. It highlights the different assessment tools currently used to detect cognitive impairment, functional impairment, and neuropsychiatric symptoms, and how to administer the commonly used tests. It includes an overview of the wide range of cognitive tests assessing different domains of cognition that are often incorporated in comprehensive cognitive assessments. Endpoints used in clinical practice and in AD clinical trials as well the meaning and measurement of clinical meaningfulness are also explored. Finally, the role of telemedicine in the management of AD is discussed including examples of validated assessments for remote administration.
Fluid biomarkers to increase diagnostic accuracy in the early diagnosis of Alzheimer’s disease: what, when, and how?
Dr. Ging-Yuek Robin Hsiung & Dr. Louis Verret
Tuesday, June 14, 2022 – 7 pm to 8:30 pm ET
This webinar explores the core cerebrospinal fluid (CSF) biomarkers (Aβ1–42, Aβ42/40, p-tau, and t-tau) in relation to the pathological changes associated with Alzheimer’s disease (AD). It describes how these core CSF biomarkers can support the early diagnosis of AD, and how emerging fluid biomarkers may be used as a complement to these core biomarkers for the diagnosis and prognosis of AD. This presentation also describes how to conduct a lumbar puncture with an emphasis on the importance of following standardized procedures for CSF sampling, storing, and testing. The clinical utility of CSF biomarker ratios, and considerations for biomarker disclosure are also addressed.
Imaging biomarkers to facilitate an early diagnosis of Alzheimer’s disease: what lies beneath?
Dr. Sandra E. Black & Dr. Jean-Paul Soucy
Monday, June 20, 2022 – 7 pm to 8:30 pm ET
This webinar will review the various imaging modalities that can be used to support a diagnosis of Alzheimer’s disease (AD) including magnetic resonance imaging (MRI), computed tomography (CT) scanning, and amyloid and fluorodeoxyglucose positron emission tomography (FDG-PET), as well as tau PET, which is not yet approved in Canada but is currently being researched as a promising diagnostic marker. The presentation also addresses specifically the information provided by MRI and high-resolution CT in AD diagnosis, and describes the role of amyloid PET, FDG-PET, and single photon emission computed tomography regional cerebral blood flow (SPECT rCBF) in supporting a diagnosis of AD.
Fluid biomarkers to increase diagnostic accuracy in the early diagnosis of Alzheimer’s disease: what, when, and how? (French Session)
Dr. Serge Gauthier and Dr. Louis Verret
Wednesday, June 22, 2022 – 7 pm to 8:30 pm ET
This webinar explores the core cerebrospinal fluid (CSF) biomarkers (Aβ1–42, Aβ42/40, p-tau, and t-tau) in relation to the pathological changes associated with Alzheimer’s disease (AD). It describes how these core CSF biomarkers can support the early diagnosis of AD, and how emerging fluid biomarkers may be used as a complement to these core biomarkers for the diagnosis and prognosis of AD. This presentation also describes how to conduct a lumbar puncture with an emphasis on the importance of following standardized procedures for CSF sampling, storing, and testing. The clinical utility of CSF biomarker ratios, and considerations for biomarker disclosure are also addressed.
Imaging biomarkers to facilitate an early diagnosis of Alzheimer’s disease: what lies beneath? (French Session)
Dr. Serge Gauthier & Dr. Jean-Paul Soucy
Wednesday, July 6, 2022 – 7 pm to 8:30 pm ET
This webinar will review the various imaging modalities that can be used to support a diagnosis of Alzheimer’s disease (AD) including magnetic resonance imaging (MRI), computed tomography (CT) scanning, and amyloid and fluorodeoxyglucose positron emission tomography (FDG-PET), as well as tau PET, which is not yet approved in Canada but is currently being researched as a promising diagnostic marker. The presentation also addresses specifically the information provided by MRI and high-resolution CT in AD diagnosis, and describes the role of amyloid PET, FDG-PET, and single photon emission computed tomography regional cerebral blood flow (SPECT rCBF) in supporting a diagnosis of AD.
A paradigm shift in Alzheimer’s disease: detection and management of ARIA
Dr. Serge Gauthier & Dr. Sean Symons
Monday, July 11, 2022 – 7 pm to 8:30 pm ET
This webinar provides an overview of the detection and management of amyloid-related imaging abnormalities due to vasogenic edema (ARIA-E) and amyloid-related imaging abnormalities due to micro-hemorrhages and macro-hemorrhages (ARIA-H). It explores the proposed mechanisms of disease and known risk factors of ARIA-E and ARIA-H, and examines the clinical relevance of ARIA-E and ARIA-H based on observations from clinical trials of anti-Aβ monoclonal antibodies. Supported by numerous imaging scans, the presentation describes how to identify ARIA-E and ARIA-H and how to distinguish them from other pathologies as well as how to manage ARIA in symptomatic versus asymptomatic patients with Alzheimer’s disease (AD).
A paradigm shift in Alzheimer’s disease: detection and management of ARIA (French Session)
Dr. Serge Gauthier & Dr. Louis Verret
Wednesday, July 13, 2022 – 7 pm to 8:30 pm ET
This webinar provides an overview of the detection and management of amyloid-related imaging abnormalities due to vasogenic edema (ARIA-E) and amyloid-related imaging abnormalities due to micro-hemorrhages and macro-hemorrhages (ARIA-H). It explores the proposed mechanisms of disease and known risk factors of ARIA-E and ARIA-H, and examines the clinical relevance of ARIA-E and ARIA-H based on observations from clinical trials of anti-Aβ monoclonal antibodies. Supported by numerous imaging scans, the presentation describes how to identify ARIA-E and ARIA-H and how to distinguish them from other pathologies as well as how to manage ARIA in symptomatic versus asymptomatic patients with Alzheimer’s disease (AD).
Loading…
Confirm that you are not a robot.
